TABLE 1.
Mean tedizolid pharmacokinetics in the renal-impairment studya
| Study group | Cmax (μg/ml) | Tmax (h) | AUC0–t (μg · h/ml) | AUC0–∞ (μg · h/ml) | t1/2 (h) |
|---|---|---|---|---|---|
| Control (n = 8) | 3.11 (0.75) | 1.00 (1.00–2.50) | 32.02 (9.32) | 32.43 (9.53) | 12.25 (2.04) |
| Severe renal impairment (n = 8) | 3.12 (0.85) | 1.26 (1.00–2.00) | 29.69 (8.93) | 29.99 (8.97) | 12.85 (2.28) |
| Predialysis infusion (n = 7) | 2.53 (0.95) | 1.00 (0.50–1.50) | 22.97 (8.02) | 23.15 (8.10) | 11.41 (1.78) |
| Postdialysis infusion (n = 8) | 2.86 (1.01) | 1.50 (1.00–1.50) | 20.81 (4.65) | 21.01 (4.71) | 11.73 (2.33) |
a
AUC0–t, integrated area under the curve based on samples from time zero to the time of the last collected sample; AUC0–∞, area under the curve based on the terminal rate constant; Cmax, maximum concentration observed with a 200-mg dose; t1/2, tedizolid half-life; Tmax, time to reach the maximum concentration. Pharmacokinetic parameters are presented as means (standard deviations), except for Tmax values, which are presented as medians (ranges).